MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1164/rccm.201602-0402oc

Медицинская библиотека · American journal of respiratory and critical care medicine · 2017

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Raghu Ganesh, Wells Athol U, Nicholson Andrew G, Richeldi Luca, Flaherty Kevin R, Le Maulf Florence, Stowasser Susanne, Schlenker-Herceg Rozsa, Hansell David M

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

RATIONALE: In the absence of a surgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS trials of nintedanib if they had honeycombing and/or traction bronchiectasis plus reticulation, without atypical features of usual interstitial pneumonia (UIP), on high-resolution computed tomography (HRCT). Thus, the patients in these trials represented patients with definite UIP and a large subgroup of patients with possible UIP.

OBJECTIVES

To investigate the potential impact of diagnostic subgroups on the progression of IPF and the effect of nintedanib.

METHODS

We conducted a post hoc subgroup analysis of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy versus patients without either, using pooled data from the INPULSIS trials.

MEASUREMENTS AND MAIN

RESULTS

Seven hundred twenty-three (68.1%) patients had honeycombing and/or biopsy, and 338 (31.9%) patients had no honeycombing or biopsy. In these subgroups, respectively, the adjusted annual rate of decline in FVC in patients treated with placebo was -225.7 and -221.0 ml/yr, and the nintedanib versus placebo difference in the adjusted annual rate of decline in FVC was 117.0 ml/yr (95% confidence interval, 76.3-157.8) and 98.9 ml/yr (95% confidence interval, 36.4-161.5). There was no significant treatment-by-subgroup interaction (P = 0.8139). Adverse events were similar between the subgroups.

CONCLUSIONS

Patients with IPF diagnosed in clinical practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lung biopsy had disease that progressed in a similar way, and responded similarly to nintedanib, to that of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy.

Для цитирования: Raghu Ganesh, Wells Athol U, Nicholson Andrew G, Richeldi Luca, Flaherty Kevin R, Le Maulf Florence, Stowasser Susanne, Schlenker-Herceg Rozsa, Hansell David M. Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.. American journal of respiratory and critical care medicine. 2017. DOI: 10.1164/rccm.201602-0402oc.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.